Latest Bcl-2 Stories
A research article to be published on June 21, 2009 in the World Journal of Gastroenterology addresses this question.
MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida.
Looking for efficient anti-tumor drugs is a hot research area.
- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research - - University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented - MALVERN, Pa., April 21 /PRNewswire/ -- Ascenta Therapeutics announced today that the results of preclinical studies of its orally-active, small molecule, pro-apoptotic agent, AT-406, have been presented at the...
A protein called Mcl-1 plays a critical role in melanoma cell resistance to a form of apoptosis called anoikis, according to research published this week in Molecular Cancer Research.
Mitochondria are restless, continually merging and splitting. But contrary to conventional wisdom, the size of these organelles depends on more than fusion and fission, as Berman et al. show. Mitochondrial growth and degradation are also part of the equation.
- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - MALVERN, Pa., Feb.
Researchers at A*STAR's Institute of Molecular and Cell Biology (IMCB) have become the first toResearchers at A*STAR's Institute of Molecular and Cell Biology (IMCB) have become the first to discover and characterize a human protein called Bax-beta (BaxÎ²), which can potentially cause the death of cancer cells and lead to new approaches in cancer treatment. discover and characterize a human protein called Bax-beta (BaxÎ²), which can potentially cause the death of cancer cells and lead to...
Gemin X Pharmaceuticals announced today that clinical data from a Phase 1/2 study of obatoclax (GX15-070), the Company's innovative pan Bcl-2 inhibitor, will be presented during The 26th Chemotherapy Foundation Symposium being held in New York City from November 4 - 8, 2008.
Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this week demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with the Marshall Edwards, Inc.'s Phase III anti-ovarian cancer drug, phenoxodiol, produces potent synergistic anti-cancer activity against non-small cell lung carcinoma cell lines (NSCLC).
- A trick or prank.